NCT00402233 · Interventional trial
A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients
Overall registry status Completed
Phase 4
Conditions Parkinson Disease
Delaware Valley sites
- 248.622.18 Boehringer Ingelheim Investigational Site · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory